BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29924716)

  • 1. Tumor Surface Regularity at MR Imaging Predicts Survival and Response to Surgery in Patients with Glioblastoma.
    Pérez-Beteta J; Molina-García D; Ortiz-Alhambra JA; Fernández-Romero A; Luque B; Arregui E; Calvo M; Borrás JM; Meléndez B; Rodríguez de Lope Á; Moreno de la Presa R; Iglesias Bayo L; Barcia JA; Martino J; Velásquez C; Asenjo B; Benavides M; Herruzo I; Revert A; Arana E; Pérez-García VM
    Radiology; 2018 Jul; 288(1):218-225. PubMed ID: 29924716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Imaging Biomarkers in Glioblastoma: Development and Independent Validation on the Basis of Multiregion and Quantitative Analysis of MR Images.
    Cui Y; Tha KK; Terasaka S; Yamaguchi S; Wang J; Kudo K; Xing L; Shirato H; Li R
    Radiology; 2016 Feb; 278(2):546-53. PubMed ID: 26348233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphological MRI-based features provide pretreatment survival prediction in glioblastoma.
    Pérez-Beteta J; Molina-García D; Martínez-González A; Henares-Molina A; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; Martino J; Velásquez C; Meléndez-Asensio B; de Lope ÁR; Moreno R; Barcia JA; Asenjo B; Benavides M; Herruzo I; Lara PC; Cabrera R; Albillo D; Navarro M; Pérez-Romasanta LA; Revert A; Arana E; Pérez-García VM
    Eur Radiol; 2019 Apr; 29(4):1968-1977. PubMed ID: 30324390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma.
    Ingrisch M; Schneider MJ; Nörenberg D; Negrao de Figueiredo G; Maier-Hein K; Suchorska B; Schüller U; Albert N; Brückmann H; Reiser M; Tonn JC; Ertl-Wagner B
    Invest Radiol; 2017 Jun; 52(6):360-366. PubMed ID: 28079702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models.
    Kickingereder P; Burth S; Wick A; Götz M; Eidel O; Schlemmer HP; Maier-Hein KH; Wick W; Bendszus M; Radbruch A; Bonekamp D
    Radiology; 2016 Sep; 280(3):880-9. PubMed ID: 27326665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glioblastoma: does the pre-treatment geometry matter? A postcontrast T1 MRI-based study.
    Pérez-Beteta J; Martínez-González A; Molina D; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; López C; Claramonte M; Barcia JA; Iglesias L; Avecillas J; Albillo D; Navarro M; Villanueva JM; Paniagua JC; Martino J; Velásquez C; Asenjo B; Benavides M; Herruzo I; Delgado MD; Del Valle A; Falkov A; Schucht P; Arana E; Pérez-Romasanta L; Pérez-García VM
    Eur Radiol; 2017 Mar; 27(3):1096-1104. PubMed ID: 27329522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic Features on MR Imaging Classify Multifocal Glioblastomas in Different Prognostic Groups.
    Pérez-Beteta J; Molina-García D; Villena M; Rodríguez MJ; Velásquez C; Martino J; Meléndez-Asensio B; Rodríguez de Lope Á; Morcillo R; Sepúlveda JM; Hernández-Laín A; Ramos A; Barcia JA; Lara PC; Albillo D; Revert A; Arana E; Pérez-García VM
    AJNR Am J Neuroradiol; 2019 Apr; 40(4):634-640. PubMed ID: 30923085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of removed tumor volume and location on patient outcome in glioblastoma.
    Awad AW; Karsy M; Sanai N; Spetzler R; Zhang Y; Xu Y; Mahan MA
    J Neurooncol; 2017 Oct; 135(1):161-171. PubMed ID: 28685405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
    Molina D; Pérez-Beteta J; Martínez-González A; Sepúlveda JM; Peralta S; Gil-Gil MJ; Reynes G; Herrero A; De Las Peñas R; Luque R; Capellades J; Balaña C; Pérez-García VM
    PLoS One; 2016; 11(8):e0161484. PubMed ID: 27557121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?
    Li YM; Suki D; Hess K; Sawaya R
    J Neurosurg; 2016 Apr; 124(4):977-88. PubMed ID: 26495941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast-enhanced MR Imaging versus Contrast-enhanced US: A Comparison in Glioblastoma Surgery by Using Intraoperative Fusion Imaging.
    Prada F; Vitale V; Del Bene M; Boffano C; Sconfienza LM; Pinzi V; Mauri G; Solbiati L; Sakas G; Kolev V; D'Incerti L; DiMeco F
    Radiology; 2017 Oct; 285(1):242-249. PubMed ID: 28562204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioblastoma: Vascular Habitats Detected at Preoperative Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging Predict Survival.
    Juan-Albarracín J; Fuster-Garcia E; Pérez-Girbés A; Aparici-Robles F; Alberich-Bayarri Á; Revert-Ventura A; Martí-Bonmatí L; García-Gómez JM
    Radiology; 2018 Jun; 287(3):944-954. PubMed ID: 29357274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Automated Volumetric Analysis of Postoperative Magnetic Resonance Imaging Predicts Survival in Patients with Glioblastoma.
    Krivoshapkin AL; Sergeev GS; Gaytan AS; Kalneus LE; Kurbatov VP; Abdullaev OA; Salim N; Bulanov DV; Simonovich AE
    World Neurosurg; 2019 Jun; 126():e1510-e1517. PubMed ID: 30910753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions.
    Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH
    Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of a MRI-Based Radiomics Prognostic Classifier in Patients with Primary Glioblastoma Multiforme.
    Chen X; Fang M; Dong D; Liu L; Xu X; Wei X; Jiang X; Qin L; Liu Z
    Acad Radiol; 2019 Oct; 26(10):1292-1300. PubMed ID: 30660472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of FLAIR Volume Changes in Glioblastoma and Prediction of Survival.
    Grossman R; Shimony N; Shir D; Gonen T; Sitt R; Kimchi TJ; Harosh CB; Ram Z
    Ann Surg Oncol; 2017 Mar; 24(3):794-800. PubMed ID: 27766560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma.
    Auer TA; Della Seta M; Collettini F; Chapiro J; Zschaeck S; Ghadjar P; Badakhshi H; Florange J; Hamm B; Budach V; Kaul D
    Acta Radiol; 2021 Sep; 62(9):1200-1207. PubMed ID: 32938221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome.
    Kotrotsou A; Elakkad A; Sun J; Thomas GA; Yang D; Abrol S; Wei W; Weinberg JS; Bakhtiari AS; Kircher MF; Luedi MM; de Groot JF; Sawaya R; Kumar AJ; Zinn PO; Colen RR
    J Neurooncol; 2018 Aug; 139(1):125-133. PubMed ID: 29619649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elderly patients with newly diagnosed glioblastoma: can preoperative imaging descriptors improve the predictive power of a survival model?
    Park M; Lee SK; Chang JH; Kang SG; Kim EH; Kim SH; Song MK; Ma BG; Ahn SS
    J Neurooncol; 2017 Sep; 134(2):423-431. PubMed ID: 28674975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
    Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
    J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.